Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.

Tedeschi A; Frustaci AM; Menna P; Minotti G

doi:10.1038/s41375-025-02824-y

← 뒤로

Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.

Leukemia 2026 Vol.40(1) p. 261

Tedeschi A, Frustaci AM, Menna P, Minotti G

원문 ↗ DOI ↗ BibTeX ↓ RIS ↓

이 논문을 인용하기

BibTeX ↓ RIS ↓

APA Tedeschi A, Frustaci AM, et al. (2026). Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.. Leukemia, 40(1), 261. https://doi.org/10.1038/s41375-025-02824-y

MLA Tedeschi A, et al.. "Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.." Leukemia, vol. 40, no. 1, 2026, pp. 261.

PMID 41331358

DOI 10.1038/s41375-025-02824-y

같은 제1저자의 인용 많은 논문 (1)

Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.
Leukemia 2025